Decreased level of soluble receptor activator of nuclear factor-κβ ligand (sRANKL) in overweight and obese children.
OPG/sRANKL ratio
cardiovascular risk factors
children
obesity
sRANKL
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
06
2022
accepted:
18
07
2022
entrez:
5
9
2022
pubmed:
6
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Childhood obesity contributes to the development of cardiovascular diseases. The molecular pathway - receptor activator of nuclear factor-κβ ligand (RANKL), its receptor RANK and osteoprotegerin (OPG) - takes part not only in bone metabolism but is also involved in the atherosclerosis process. RANKL stimulates osteogenic differentiation and calcification of vascular smooth cells. The associations between the OPG-sRANKL system and various cardiovascular risk factors were displayed. We aimed to evaluate the relationships between serum sRANKL (soluble RANKL) levels and the OPG/sRANKL ratio with cardiometabolic risk factors in overweight and obese children. The study included 70 children with overweight and obesity (mean age 13.0 ± 2.8) and 35 age-matched normal weight, healthy peers as a control group. In all patients, anthropometric measurements and laboratory tests were performed. Additionally, an oral glucose tolerance test (OGTT) was made only in overweight and obese children. Atherogenic and insulin resistance indices were calculated. Overweight and obese children had lower sRANKL levels compared to the control group (median 276.95 vs 325.90, p=0.011), and consequently a higher OPG/sRANKL ratio (0.02 vs 0.01, p = 0.013). The studied children in the lowest quartile of sRANKL levels had higher body weight, Body Mass Index, waist circumference and increased glucose and insulin levels 60 minutes after OGTT and higher uric acid values compared to children in the highest quartile. In multivariable linear regression analysis sRANKL negatively correlated only with uric acid (β = - 0.508, p = 0.041). No association was found for the OPG/sRANKL ratio. Excess fat mass seems to alter the OPG/RANKL ratio mainly by reducing serum sRANKL levels. The correlation between sRANKL and uric acid may suggest a contribution of the OPG-sRANKL system in the cardiometabolic process, but that observation should be confirmed in future studies.
Identifiants
pubmed: 36060948
doi: 10.3389/fendo.2022.963467
pmc: PMC9437335
doi:
Substances chimiques
Ligands
0
Osteoprotegerin
0
RANK Ligand
0
TNFRSF11B protein, human
0
TNFSF11 protein, human
0
Uric Acid
268B43MJ25
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
963467Informations de copyright
Copyright © 2022 Erazmus, Rumińska, Witkowska-Sędek, Kucharska, Stelmaszczyk-Emmel, Majcher and Pyrżak.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1849-54
pubmed: 20448212
Semin Nephrol. 2005 Jan;25(1):39-42
pubmed: 15660333
Clin Endocrinol (Oxf). 2004 Jan;60(1):87-91
pubmed: 14678293
Bone. 2011 Feb;48(2):189-96
pubmed: 20932948
Kidney Int. 2005 May;67(5):1739-42
pubmed: 15840020
Hum Biol. 1988 Oct;60(5):709-23
pubmed: 3224965
Inflamm Regen. 2016 Aug 1;36:10
pubmed: 29259683
Circulation. 2003 Mar 25;107(11):e76; author reply e76
pubmed: 12654623
Pediatrics. 2002 Sep;110(3):e29
pubmed: 12205279
Rheumatology (Oxford). 2005 Dec;44(12):1503-6
pubmed: 16219645
Eur J Pediatr. 2011 May;170(5):599-609
pubmed: 20972688
Osteoporos Int. 2016 Apr;27(4):1631-1643
pubmed: 26588909
Circulation. 2007 Jul 24;116(4):385-91
pubmed: 17620507
Histol Histopathol. 2008 Apr;23(4):497-506
pubmed: 18228207
Medicine (Baltimore). 2018 Apr;97(17):e0432
pubmed: 29702995
Cardiovasc Endocrinol Metab. 2018 May 16;7(2):28-33
pubmed: 31646276
Nutrients. 2019 Sep 05;11(9):
pubmed: 31491937
J Clin Endocrinol Metab. 2013 Sep;98(9):3856-63
pubmed: 23796564
BMC Obes. 2017 Jul 3;4:25
pubmed: 28690854
Diagnostics (Basel). 2021 Dec 28;12(1):
pubmed: 35054232
Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):975-80
pubmed: 19325145
Cytokine Growth Factor Rev. 2013 Oct;24(5):401-9
pubmed: 23827649
Thrombosis. 2012;2012:306263
pubmed: 22577539
Blood Purif. 2009;28(4):342-5
pubmed: 19729902
Nat Med. 2013 Mar;19(3):358-63
pubmed: 23396210
Circulation. 2005 May 17;111(19):2461-8
pubmed: 15883214
Arthritis Res Ther. 2007;9 Suppl 1:S1
pubmed: 17634140
Eur J Clin Nutr. 1990 Jan;44(1):45-60
pubmed: 2354692
Acta Biochim Pol. 2018 Nov 19;65(4):605-611
pubmed: 30451245
J Clin Endocrinol Metab. 2007 Aug;92(8):3025-32
pubmed: 17519311
Minerva Endocrinol. 2018 Mar;43(1):19-26
pubmed: 28146138
J Pediatr Endocrinol Metab. 2018 Nov 27;31(11):1169-1177
pubmed: 30352039
Int J Paediatr Dent. 2018 Nov;28(6):633-640
pubmed: 30252176
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
J Clin Invest. 1993 Apr;91(4):1800-9
pubmed: 8473518
N Engl J Med. 1998 Jun 4;338(23):1650-6
pubmed: 9614255
Panminerva Med. 2014 Sep;56(3):221-5
pubmed: 25056244
Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):857-63
pubmed: 16424351
PLoS One. 2013 Sep 05;8(9):e74211
pubmed: 24040204
Diabetes Metab Syndr Obes. 2021 Feb 11;14:627-635
pubmed: 33603427
J Clin Diagn Res. 2015 Dec;9(12):BC01-4
pubmed: 26816879
Curr Rev Musculoskelet Med. 2009 Mar;2(1):56-64
pubmed: 19468919
Cent Eur J Immunol. 2020;45(4):461-468
pubmed: 33658893
Int J Mol Sci. 2019 Feb 06;20(3):
pubmed: 30736365
Eur J Endocrinol. 2009 Jan;160(1):45-52
pubmed: 18952765
J Biol Chem. 2001 Jun 8;276(23):20659-72
pubmed: 11274143
Nutrients. 2021 Nov 22;13(11):
pubmed: 34836431
J Pediatr Endocrinol Metab. 2009 Dec;22(12):1099-104
pubmed: 20333868
J Clin Endocrinol Metab. 2004 Jun;89(6):2526-39
pubmed: 15181020
Metabolism. 2011 Jul;60(7):994-1000
pubmed: 21087777
Atherosclerosis. 2009 Jun;204(2):321-9
pubmed: 19007931
J Endocrinol Invest. 2019 Apr;42(4):427-434
pubmed: 30132289
J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10
pubmed: 10902785
Front Pediatr. 2022 Jan 04;9:814166
pubmed: 35059366
Ital J Pediatr. 2017 Jan 3;43(1):3
pubmed: 28049502
Int J Prev Med. 2014 Aug;5(8):927-46
pubmed: 25489440
Mediators Inflamm. 2015;2015:597512
pubmed: 26347587